Compare Amphastar Pharmaceuticals Inc (AMPH) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Atlassian Corporation PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Atlassian Corporation PLC trades at $154.19 (market cap $38.54B). The key difference: Atlassian Corporation PLC is far larger — about 44.6× Amphastar Pharmaceuticals Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | TEAM | |
|---|---|---|
Market Cap | $863.95M | $38.54B |
Sector | Health | Technology |
52-Week High | $30.81 | $182.36 |
52-Week Low | $16.87 | $57.15 |
Enterprise Value | $1.26B | $38.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Atlassian Corporation (TEAM) surged 35.31% to $149.07 following a strong Q4 2026 earnings beat, with revenue up 28% year-over-year to $1.77 billion and cloud revenue accelerating to 31%. The stock is trading near its pivot point of $148, with bullish technical signals from moving averages but overbought RSI readings. Analysts maintain a strong buy consensus with a $161.93 price target, citing enterprise deal expansion and AI platform adoption as key growth drivers.
Outlook remains positive due to robust revenue growth and margin improvement, but risks include high valuation multiples (P/S 5.9, EV/EBITDA 178.27) and persistent net losses. Investors should weigh the company's cloud momentum against profitability challenges and macroeconomic uncertainty impacting software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
